Abstract
Falcipain-2 (FP2) is an important hemoglobinase from the malaria parasite Plasmodium falciparum and a suitable target for the development of an antimalarial chemotherapy. Many reports have indicated that radical nitrogen species (RNS) including nitric oxide (NO) are inhibitors of P. falciparum growth and promoters of recovery from malaria symptoms. In this scenario, FP2 emerges as a potential target of RNS, since its inhibition partially hinders the parasite growth. We report that in vitro FP2 did not undergo S-nitrosylation when exposed to the NO-donor GSNO. However, it was modified by a combined mechanism of methionine oxidation and tyrosine nitration in response to SIN-1, and NaNO2- H2O2 treatment. The treatments with the nitrating agents caused a pronounced decrease in protease activity most likely induced by a disruption on the secondary and tertiary structure of FP2. Our data also demonstrate that at least four tyrosine residues were nitrated and found on the surface of the enzyme, partially or completely exposed to the solvent. Although performed in vitro, these results suggest that falcipain-2 may be a target of RNS activity and its inhibition could explain the hindering of the parasite growth when exposed to these radicals. The understanding of the molecular mechanisms involving free radicals and its inhibition activity towards FP2 may be effective in the development of antimalarial therapies.
Keywords: Falcipain-2, FP2, nitration, Plasmodium falciparum, S-nitrosylation, 3-nitrotyrosine.
Graphical Abstract
Protein & Peptide Letters
Title:Oxidation and Tyrosine Nitration Induce Structural Changes and Inhibits Plasmodium falciparum Falcipain-2 Activity In Vitro
Volume: 23 Issue: 6
Author(s): Jean B. Bertoldo and Hernán Terenzi
Affiliation:
Keywords: Falcipain-2, FP2, nitration, Plasmodium falciparum, S-nitrosylation, 3-nitrotyrosine.
Abstract: Falcipain-2 (FP2) is an important hemoglobinase from the malaria parasite Plasmodium falciparum and a suitable target for the development of an antimalarial chemotherapy. Many reports have indicated that radical nitrogen species (RNS) including nitric oxide (NO) are inhibitors of P. falciparum growth and promoters of recovery from malaria symptoms. In this scenario, FP2 emerges as a potential target of RNS, since its inhibition partially hinders the parasite growth. We report that in vitro FP2 did not undergo S-nitrosylation when exposed to the NO-donor GSNO. However, it was modified by a combined mechanism of methionine oxidation and tyrosine nitration in response to SIN-1, and NaNO2- H2O2 treatment. The treatments with the nitrating agents caused a pronounced decrease in protease activity most likely induced by a disruption on the secondary and tertiary structure of FP2. Our data also demonstrate that at least four tyrosine residues were nitrated and found on the surface of the enzyme, partially or completely exposed to the solvent. Although performed in vitro, these results suggest that falcipain-2 may be a target of RNS activity and its inhibition could explain the hindering of the parasite growth when exposed to these radicals. The understanding of the molecular mechanisms involving free radicals and its inhibition activity towards FP2 may be effective in the development of antimalarial therapies.
Export Options
About this article
Cite this article as:
B. Bertoldo Jean and Terenzi Hernán, Oxidation and Tyrosine Nitration Induce Structural Changes and Inhibits Plasmodium falciparum Falcipain-2 Activity In Vitro, Protein & Peptide Letters 2016; 23 (6) . https://dx.doi.org/10.2174/0929866523666160411144635
DOI https://dx.doi.org/10.2174/0929866523666160411144635 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Current Medicinal Chemistry Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine Revision and Implementation of “Clinical Guideline for Tuberculosis and HIV in Prisons”, Great Tehran Prison, Iran
Infectious Disorders - Drug Targets Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Significant Induction of Soluble TNFR2 Compared with TNFR1 in Serum Samples of HIV Patients with or without Antiretroviral Medication
Infectious Disorders - Drug Targets Isocitrate Lyase: A Potential Target for Anti-Tubercular Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Infectious Complications with Anti-TNFα Therapy in Rheumatic Diseases: A Review
Recent Patents on Inflammation & Allergy Drug Discovery New Targets, New Hope: Novel Drug Targets for Curbing Malaria
Mini-Reviews in Medicinal Chemistry Reaction of Some Substituted 3-Aryl-4-formylsydnones with Tetra-Oacetyl- β-D-galactopyranosyl)thiosemicarbazide
Letters in Organic Chemistry Design of Novel Phosphopantetheine Adenylyltransferase Inhibitors: A Potential New Approach to Tackle <i>Mycobacterium tuberculosis</i>
Current Topics in Medicinal Chemistry Macrophage Response to Mycobacterium tuberculosis During HIV Infection Relationships Between Macrophage Activation and Apoptosis.
Current Molecular Medicine Quinolones: Action and Resistance Updated
Current Topics in Medicinal Chemistry Alcohol Abuse, Immunosuppression, and Pulmonary Infection
Current Drug Abuse Reviews Recent Advances in the Synthesis of New Antimycobacterial Agents Based on the 1H-1,2,3-Triazoles
Current Topics in Medicinal Chemistry Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Molecular Detection of Bacteria Producing Newer Types of β-Lactamases
Current Genomics Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Current Gene Therapy Costing Human Rights and Community Support Interventions as a Part of Universal Access to HIV Treatment and Care in a Southern African Setting
Current HIV Research Synthesis and Cytotoxic Evaluation of Disubstituted N-Acylhydrazones Pyrazinecarbohydrazide Derivatives
Letters in Drug Design & Discovery